|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Poggio F, Ceppi M, Lambertini M, Bruzzi P,
Ugolini D, Bighin C, Levaggi A, Giraudi S, D'Alonzo A, Vaglica M,
et al: Concurrent versus sequential adjuvant chemo-endocrine
therapy in hormone-receptor positive early stage breast cancer
patients: A systematic review and meta-analysis. Breast.
33:104–108. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang Y and Liu Y: Endocrine therapy for
breast cancer: Past and present. Zhonghua Yi Shi Za Zhi. 45:28–32.
2015.(In Chinese). PubMed/NCBI
|
|
4
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG), ; Davies C, Godwin J, Gray R, Clarke
M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, et al: Relevance
of breast cancer hormone receptors and other factors to the
efficacy of adjuvant tamoxifen: patient-level metaanalysis of
randomised trials. Lancet. 378:771–784. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Burstein HJ, Temin S, Anderson H, Buchholz
TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky
AJ, et al: Adjuvant endocrine therapy for women with hormone
receptor-positive breast cancer: American society of clinical
oncology clinical practice guideline focused update. J Clin Oncol.
32:2255–2269. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chang M: Tamoxifen resistance in breast
cancer. Biomol Ther (Seoul). 20:256–267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park M, Kim J, Phuong NTT, Park JG, Park
JH, Kim YC, Baek MC, Lim SC and Kang KW: Involvement of the P2X7
receptor in the migration and metastasis of tamoxifen-resistant
breast cancer: Effects on small extracellular vesicles production.
Sci Rep. 9:115872019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
De Marchi T, Liu NQ, Stingl C, Timmermans
MA, Smid M, Look MP, Tjoa M, Braakman RB, Opdam M, Linn SC, et al:
4-protein signature predicting tamoxifen treatment outcome in
recurrent breast cancer. Mol Oncol. 10:24–39. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang J, Zhou C, Jiang H, Liang L, Shi W,
Zhang Q, Sun P, Xiang R, Wang Y and Yang S: ZEB1 induces ER-α
promoter hypermethylation and confers antiestrogen resistance in
breast cancer. Cell Death Dis. 8:e27322017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peng WX, Koirala P and Mo YY:
LncRNA-mediated regulation of cell signaling in cancer. Oncogene.
36:5661–5667. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peng F, Li TT, Wang KL, Xiao GQ, Wang JH,
Zhao HD, Kang ZJ, Fan WJ, Zhu LL, Li M, et al: H19/let-7/LIN28
reciprocal negative regulatory circuit promotes breast cancer stem
cell maintenance. Cell Death Dis. 8:e25692017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu QN, Wang G, Guo Y, Peng Y, Zhang R,
Deng JL, Li ZX and Zhu YS: LncRNA H19 is a major mediator of
doxorubicin chemoresistance in breast cancer cells through a
cullin4A-MDR1 pathway. Oncotarget. 8:91990–92003. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Basak P, Chatterjee S, Bhat V, Su A, Jin
H, Lee-Wing V, Liu Q, Hu P, Murphy LC and Raouf A: Long non-coding
RNA H19 acts as an estrogen receptor modulator that is required for
endocrine therapy resistance in ER+ breast cancer cells. Cell
Physiol Biochem. 51:1518–1532. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu Y, Zhou Y, He J, Sun H and Jin Z: Long
non-coding RNA H19 mediates ovarian cancer cell
cisplatin-resistance and migration during EMT. Int J Clin Exp
Pathol. 12:2506–2515. 2019.PubMed/NCBI
|
|
15
|
Ye Y, Guo J, Xiao P, Ning J, Zhang R, Liu
P, Yu W, Xu L, Zhao Y and Yu J: Macrophages-induced long noncoding
RNA H19 up-regulation triggers and activates the miR-193b/MAPK1
axis and promotes cell aggressiveness in hepatocellular carcinoma.
Cancer Lett. 469:310–322. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou W, Ye XL, Xu J, Cao MG, Fang ZY, Li
LY, Guan GH, Liu Q, Qian YH and Xie D: The lncRNA H19 mediates
breast cancer cell plasticity during EMT and MET plasticity by
differentially sponging miR-200b/c and let-7b. Sci Signal.
10:eaak95572017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shanmugam MK, Rane G, Kanchi MM, Arfuso F,
Chinnathambi A, Zayed ME, Alharbi SA, Tan BK, Kumar AP and Sethi G:
The multifaceted role of curcumin in cancer prevention and
treatment. Molecules. 20:2728–2769. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cao L, Xiao X, Lei J, Duan W, Ma Q and Li
W: Curcumin inhibits hypoxia-induced epithelial mesenchymal
transition in pancreatic cancer cells via suppression of the
hedgehog signaling pathway. Oncol Rep. 35:3728–3734. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gallardo M and Calaf GM: Curcumin inhibits
invasive capabilities through epithelial mesenchymal transition in
breast cancer cell lines. Int J Oncol. 49:1019–1027. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li G, Wang Z, Chong T, Yang J, Li H and
Chen H: Curcumin enhances the radiosensitivity of renal cancer
cells by suppressing NF-κB signaling pathway. Biomed Pharmacother.
94:974–981. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang J, Xie S, Yang J, Xiong H, Jia Y,
Zhou Y, Chen Y, Ying X, Chen C, Ye C, et al: The long noncoding RNA
H19 promotes tamoxifen resistance in breast cancer via autophagy. J
Hematol Oncol. 12:812019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Y, Shi J, Chai K, Ying X and Zhou BP:
The Role of Snail in EMT and Tumorigenesis. Curr Cancer Drug
Targets. 13:963–972. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mills JN, Rutkovsky AC and Giordano A:
Mechanisms of resistance in estrogen receptor positive breast
cancer: Overcoming resistance to tamoxifen/aromatase inhibitors.
Curr Opin Pharmacol. 41:59–65. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Si H, Chen P, Li H and Wang X: Long
non-coding RNA H19 regulates cell growth and metastasis via miR-138
in breast cancer. Am J Transl Res. 11:3213–3225. 2019.PubMed/NCBI
|
|
26
|
Liao S, Yu C, Liu H, Zhang C, Li Y and
Zhong X: Long non-coding RNA H19 promotes the proliferation and
invasion of lung cancer cells and regulates the expression of
E-cadherin, N-cadherin, and vimentin. OncoTargets Ther.
12:4099–4107. 2019. View Article : Google Scholar
|
|
27
|
Jiang GM, Wang HS, Zhang F, Zhang KS, Liu
ZC, Fang R, Wang H, Cai SH and Du J: Histone deacetylase inhibitor
induction of epithelial-mesenchymal transitions via up-regulation
of Snail facilitates cancer progression. Biochim Biophys Acta.
1833:663–671. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kokkinos MI, Wafai R, Wong MK, Newgreen
DF, Thompson EW and Waltham M: Vimentin and epithelial-mesenchymal
transition in human breast cancer - observations in vitro and in
vivo. Cells Tissues Organs. 185:191–203. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Al Khatib AM, Stepan AE, Margaritescu C,
Simionescu C and Ciurea RN: E-cadherin and snail immunoexpression
in colorectal adenocarcinomas. Curr Health Sci J. 45:204–209.
2019.PubMed/NCBI
|
|
30
|
Hu S, Xu Y, Meng L, Huang L and Sun H:
Curcumin inhibits proliferation and promotes apoptosis of breast
cancer cells. Exp Ther Med. 16:1266–1272. 2018.PubMed/NCBI
|
|
31
|
Cao MT, Liu HF, Liu ZG, Xiao P, Chen JJ,
Tan Y, Jiang XX, Jiang ZC, Qiu Y, Huang HJ, et al: Curcumin
downregulates the expression of Snail via suppressing Smad2 pathway
to inhibit TGF-β1-induced epithelial-mesenchymal transitions in
hepatoma cells. Oncotarget. 8:108498–108508. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li W, Jiang Z, Xiao X, Wang Z, Wu Z, Ma Q
and Cao L: Curcumin inhibits superoxide dismutase-induced
epithelial-to-mesenchymal transition via the PI3K/Akt/NF-κB pathway
in pancreatic cancer cells. Int J Oncol. 52:1593–1602.
2018.PubMed/NCBI
|
